Company Overview
Rays of Belief Limited operates as a holistic care provider for children with autism, ADHD, Down syndrome, and other developmental delays and disorders in India. The company provides subscription-based, guided therapy programs designed to empower parents of children with special needs. The company operates through its brand, Mom's Belief, a child development and therapy organization that creates personalized therapeutic programs for children with autism and other developmental delays. The company's services include occupational therapy to enhance motor skills and daily functioning; speech therapy to improve communication and language abilities; special education and individualized learning support for children with diverse needs; Applied Behaviour Analysis (ABA), a behaviour-based intervention for skill development; language and communication therapy to strengthen verbal and social communication; and adult counselling to support parents and caregivers. Rays of Belief Limited was incorporated in 2017 and is headquartered in Gurugram, India. Rays of Belief Limited operates as a subsidiary of Carving Futures Pte. Ltd.
Why Investors Should Care
Generates a return on equity of 16.1%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 21.5%.
Net profit has compounded at 52.9% per year over the last five years.
Revenue has grown at a 54.5% CAGR over the past five years.
Trades at a P/E of 1.1, below the sector median of 42.5.
Carries low leverage with a debt-to-equity ratio of 0.30.
Recent Developments
- Mar 2026 Revenue of ₹81.66 Cr (+11.6% YoY); net profit ₹4.96 Cr.
- Trailing 12 Months Year-on-year growth — revenue +11.7%, earnings -24.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 54.5%, profit CAGR 52.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 54.53% |
| 1 Year: | 11.65% |
Compounded Profit Growth
| 5 Years: | 52.88% |
| 1 Year: | -24.65% |
Stock Price Performance
| 1 Year: | - |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
P/E of 1.09 is below the sector median of 42.46 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 21.5%.
- Compounding revenue at 54.5% over 5 years.
- Profit CAGR of 52.9% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MOMSBELIEF MOMSBELIEF.NS NSEPHARMA | 228.34 | 1.09 | ₹477.27 Cr | 0.00% | 21.47% | 16.10% | 54.53% | 52.88% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,864.90 | 37.04 | ₹4.47 L Cr | 0.85% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,488.00 | 86.17 | ₹2.52 L Cr | 0.31% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,930.00 | 78.88 | ₹1.88 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,967.00 | 61.87 | ₹1.29 L Cr | 0.23% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 693.90 | 184.55 | ₹1.20 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,127.40 | 25.11 | ₹1.12 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,363.10 | 32.72 | ₹1.10 L Cr | 0.94% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,937.00 | 95.65 | ₹1.05 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 22.13 Cr | 30.61 Cr | 73.14 Cr | 81.66 Cr |
| Cost of Revenue | 5.40 L | 26.40 L | - | 32.00 L |
| Gross Profit | 22.08 Cr | 30.34 Cr | - | 81.34 Cr |
| Operating Expenses | 30.41 Cr | 30.17 Cr | 71.62 Cr | 73.28 Cr |
| Operating Income | -8.33 Cr | 17.80 L | 1.52 Cr | 8.06 Cr |
| EBITDA | -7.08 Cr | 1.65 Cr | 3.84 Cr | 12.31 Cr |
| Interest Expense | 13.70 L | 14.60 L | 59.30 L | 1.10 Cr |
| Pretax Income | -8.46 Cr | 10.00 L | 1.05 Cr | 6.90 Cr |
| Tax Provision | 0 | -75.30 L | -5.53 Cr | 1.94 Cr |
| Net Income | -8.46 Cr | 85.30 L | 6.58 Cr | 4.96 Cr |
| Diluted EPS | -4.05 | 0.41 | 210.24 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 7.78 Cr | 12.89 Cr | 37.86 Cr | 50.89 Cr |
| Current Assets | 5.54 Cr | 7.15 Cr | 17.75 Cr | 32.77 Cr |
| Cash & Equivalents | 3.90 Cr | 4.29 Cr | 6.42 Cr | 3.25 Cr |
| Inventory | 10.60 L | - | 0 | - |
| Receivables | 4.40 L | 17.60 L | 5.72 Cr | 18.09 Cr |
| Total Liabilities | 3.42 Cr | 7.12 Cr | 20.30 Cr | 20.08 Cr |
| Current Liabilities | 2.72 Cr | 3.67 Cr | 12.10 Cr | 13.62 Cr |
| Long Term Debt | 0 | 0 | 6.25 Cr | 2.75 Cr |
| Total Debt | 1.41 Cr | 2.13 Cr | 9.23 Cr | 9.32 Cr |
| Total Equity | 4.36 Cr | 5.78 Cr | 17.57 Cr | 30.81 Cr |
| Shares Outstanding | 2.09 Cr | 2.09 Cr | 2.09 Cr | 2.09 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | -6.86 Cr | 2.10 Cr | -1.81 Cr | -1.94 Cr |
| Investing Cash Flow | 1.52 Cr | -2.75 Cr | -2.04 Cr | -6.18 Cr |
| Financing Cash Flow | 7.56 Cr | 1.04 Cr | 4.90 Cr | 6.04 Cr |
| Capital Expenditure | -71.40 L | -1.49 Cr | -1.85 Cr | -1.14 Cr |
| Free Cash Flow | -7.57 Cr | 60.90 L | -3.66 Cr | -3.08 Cr |
| Net Change in Cash | 2.21 Cr | 38.80 L | 1.05 Cr | -2.09 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 99.8% | 99.1% | - | 99.6% |
| Operating Margin % | -37.6% | 0.6% | 2.1% | 9.9% |
| Net Margin % | -38.2% | 2.8% | 9.0% | 6.1% |
| ROE % | -194.1% | 14.8% | 37.5% | 16.1% |
| ROCE % | -164.7% | 1.9% | 5.9% | 21.6% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MOMSBELIEF
MOMSBELIEF — Frequently Asked Questions
What is the current share price of MOMSBELIEF?
As of 2026-09-10 05:11 IST, MOMSBELIEF trades at ₹228.34 on NSE. Its 52-week range is ₹228.34 to ₹228.34.
What is the market capitalisation of MOMSBELIEF?
MOMSBELIEF has a market capitalisation of ₹477.27 Cr on NSE.
What is the P/E ratio of MOMSBELIEF?
MOMSBELIEF trades at a trailing price-to-earnings (P/E) ratio of 1.09. The industry average P/E is 42.46. Its price-to-book (P/B) ratio is 15.49.
What is the return on equity (ROE) of MOMSBELIEF?
MOMSBELIEF has a return on equity (ROE) of 16.10%. Its return on capital employed (ROCE) is 21.47%.
Is MOMSBELIEF a good stock to buy?
This page provides a data-driven analysis of MOMSBELIEF, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.